

# Supporting Information

## Chemical Constituents of the Deep-Sea-Derived *Penicillium citreonigrum* MCCC 3A00169 and Their Antiproliferative Effects

Zheng-Biao Zou <sup>1,2,†</sup>, Gang Zhang <sup>3,†</sup>, Yu-Qi Zhou <sup>4,†</sup>, Chun-Lan Xie <sup>2</sup>, Ming-Min Xie <sup>2</sup>, Lin Xu <sup>2</sup>, You-Jia Hao <sup>2</sup>, Lian-Zhong Luo <sup>3</sup>, Xiao-Kun Zhang <sup>4,\*</sup>, Xian-Wen Yang <sup>2,\*</sup>, and Jun-Song Wang <sup>1,\*</sup>

<sup>1</sup> Center for Molecular Metabolism, School of Environmental and Biological Engineering, Nanjing University of Science and Technology, 200 Xiaolingwei Street, Nanjing 210094, China

<sup>2</sup> Key Laboratory of Marine Genetic Resources, Third Institute of Oceanography, Ministry of Natural Resources, 184 Daxue Road, Xiamen 361005, China

<sup>3</sup> Xiamen Key Laboratory of Marine Medicinal Natural Products Resources; Fujian Province Universities and Colleges Engineering Research Center for Marine Biomedical Resource Utilization; Xiamen Medica College, 1999 Guankouzhong Road, Xiamen 361023, China

<sup>4</sup> School of Pharmaceutical Sciences, Xiamen University, South Xiangan Road, Xiamen, 361102, China

\* Correspondence: wang.junsong@gmail.com (J.-S.W.); xkzhang@xmu.edu.cn (X.-K.Z.); yangxianwen@tio.org.cn (X.-W.Y.); Tel.: +86-25- 8431-5512 (J.-S.W.); +86-592-2181851 (X.-K.Z.); +86-592-2195319 (X.-W.Y.)

† These authors contributed equally to this work.

## Content

**Figure S1.** Chemical structures of compounds 7–28.

**Figure S2.** HR-ESI-MS of citreoviridin J (**1**).

**Figure S3.** <sup>1</sup>H NMR spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin J (**1**).

**Figure S4.** <sup>13</sup>C NMR and DEPT spectra (100 MHz, CD<sub>3</sub>OD) of citreoviridin J (**1**).

**Figure S5.** HMQC spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin J (**1**).

**Figure S6.** <sup>1</sup>H-<sup>1</sup>H COSY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin J (**1**).

**Figure S7.** HMBC spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin J (**1**).

**Figure S8.** NOESY spectrum of (400 MHz, CD<sub>3</sub>OD) citreoviridin J (**1**).

**Figure S9.** HR-ESI-MS of citreoviridin K (**2**).

**Figure S10.** <sup>1</sup>H NMR spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin K (**2**).

**Figure S11.** <sup>13</sup>C NMR and DEPT (100 MHz, CD<sub>3</sub>OD) of citreoviridin K (**2**).

**Figure S12.** HMQC spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin K (**2**).

**Figure S13.** <sup>1</sup>H-<sup>1</sup>H COSY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin K (**2**).

**Figure S14.** HMBC spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin K (**2**).

**Figure S15.** NOESY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin K (**2**).

**Figure S16.** HR-ESI-MS of citreoviridin L (**3**).


**Figure S17.** <sup>1</sup>H NMR spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin L (**3**).

**Figure S18.** <sup>13</sup>C NMR and DEPT (100 MHz, CD<sub>3</sub>OD) of citreoviridin L (**3**).

**Figure S19.** HMQC spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin L (**3**).

**Figure S20.** <sup>1</sup>H-<sup>1</sup>H COSY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin L (**3**).

- Figure S21.** HMBC spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin L (**3**).
- Figure S22.** NOESY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin L (**3**).
- Figure S23.** HR-ESI-MS of citreoviridin M (**4**).
- Figure S24.** <sup>1</sup>H NMR spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin M (**4**).
- Figure S25.** <sup>13</sup>C NMR and DEPT (100 MHz, CD<sub>3</sub>OD) of citreoviridin M (**4**).
- Figure S26.** HMQC spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin M (**4**).
- Figure S27.** <sup>1</sup>H-<sup>1</sup>H COSY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin M (**4**).
- Figure S28.** HMBC spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin M (**4**).
- Figure S29.** NOESY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin M (**4**).
- Figure S30.** <sup>1</sup>H NMR spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridins N and O (**5** and **6**).
- Figure S31.** Amplified <sup>1</sup>H NMR spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridins N and O (**5** and **6**).
- Figure S32.** <sup>13</sup>C NMR and DEPT (100 MHz, CD<sub>3</sub>OD) of citreoviridins N and O (**5** and **6**).
- Figure S33.** Amplified <sup>13</sup>C NMR spectrum (100 MHz, CD<sub>3</sub>OD) of citreoviridins N and O (**5** and **6**).
- Figure S34.** HMQC spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridins N and O (**5** and **6**).
- Figure S35.** <sup>1</sup>H-<sup>1</sup>H COSY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridins N and O (**5** and **6**).
- Figure S36.** HMBC spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridins N and O (**5** and **6**).
- Figure S37.** NOESY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridins N and O (**5** and **6**).
- Figure S38.** HR-ESI-MS of citreoviridin N (**5**).
- Figure S39.** <sup>1</sup>H NMR spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin N (**5**).
- Figure S40.** <sup>1</sup>H-<sup>1</sup>H COSY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin N (**5**).
- Figure S41.** NOESY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin N (**5**).
- Figure S42.** HR-ESI-MS of citreoviridin O (**6**).
- Figure S43.** <sup>1</sup>H NMR spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin O (**6**).
- Figure S44.** <sup>1</sup>H-<sup>1</sup>H COSY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin O (**6**).
- Figure S45.** NOESY spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin O (**6**).
- Figure S46.** HR-ESI-MS of pyrenocine A (**7**).
- Figure S47.** <sup>1</sup>H NMR spectrum (400 MHz, CD<sub>3</sub>OD) of pyrenocine A (**7**).
- Figure S48.** <sup>13</sup>C NMR spectrum (100 MHz, CD<sub>3</sub>OD) of pyrenocine A (**7**).
- Figure S49.** HR-ESI-MS of terrein (**14**).
- Figure S50.** <sup>1</sup>H NMR spectrum (400 MHz, CD<sub>3</sub>OD) of terrein (**14**).
- Figure S51.** <sup>13</sup>C NMR spectrum (100 MHz, CD<sub>3</sub>OD) of terrein (**14**).
- Figure S52.** HR-ESI-MS of citreoviridin (**20**).
- Figure S53.** <sup>1</sup>H NMR spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin (**20**).
- Figure S54.** <sup>13</sup>C NMR spectrum (100 MHz, CD<sub>3</sub>OD) of citreoviridin (**20**).



**Figure S1** Chemical structures of compounds 7–28.







Figure S2. HR-ESI-MS of citreoviridin J (1)




**Figure S3.**  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin J (**1**)




**Figure S4.** <sup>13</sup>C NMR and DEPT spectra (100 MHz, CD<sub>3</sub>OD) of citreoviridin J (**1**)




**Figure S5.** HMQC spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin J (**1**)



**Figure S6.**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin J (**1**)



**Figure S7.** HMBC spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin J (**1**)



**Figure S8.** NOESY spectrum of (400 MHz,  $\text{CD}_3\text{OD}$ ) citreoviridin J (**1**)





Figure S9. HR-ESI-MS of citreoviridin K (2)



**Figure S10.**  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin K (**2**)






Figure S11. <sup>13</sup>C NMR and DEPT (100 MHz, CD<sub>3</sub>OD) of citreoviridin K (2)



**Figure S12.** HMQC spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin K (**2**)



**Figure S13.**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin K (**2**)





Figure S14. HMBC spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin K (2)



**Figure S15.** NOESY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin K (**2**)





Figure S16. HR-ESI-MS of citreoviridin L (3)



**Figure S17.**  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin L (**3**)




Figure S18. <sup>13</sup>C NMR and DEPT (100 MHz, CD<sub>3</sub>OD) of citreoviridin L (3)





Figure S19. HMQC spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin L (**3**)



**Figure S20.**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin L (3)




Figure S21. HMBC spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin L (**3**)




Figure S22. NOESY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin L (3)






Figure S23. HR-ESI-MS of citreoviridin M (4)



**Figure S24.** <sup>1</sup>H NMR spectrum (400 MHz, CD<sub>3</sub>OD) of citreoviridin M (**4**)



**Figure S25.** <sup>13</sup>C NMR and DEPT (100 MHz, CD<sub>3</sub>OD) of citreoviridin M (4)







Figure S26. HMQC spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin M (4)



**Figure S27.**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin M (**4**)



**Figure S28.** HMBC spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin M (4)



**Figure S29.** NOESY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin M (**4**)









Figure S30.  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridins N and O (**5** and **6**)




**Figure S31.** Amplified  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridins N and O (**5** and **6**)




**Figure S32.**  $^{13}\text{C}$  NMR and DEPT (100 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridins N and O (**5** and **6**)



**Figure S33.** Amplified <sup>13</sup>C NMR spectrum (100 MHz, CD<sub>3</sub>OD) of citreoviridins N and O (**5** and **6**)



**Figure S34.** HMQC spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridins N and O (**5** and **6**)



**Figure S35.**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridins N and O (**5** and **6**)





Figure S36. HMBC spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridins N and O (**5** and **6**)



**Figure S37.** NOESY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridins N and O (**5** and **6**)




Figure S38. HR-ESI-MS of citreoviridin N (**5**)






Figure S39.  ${}^1\text{H}$  NMR spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin N (**5**)



**Figure S40.**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin N (**5**)



**Figure S41.** NOESY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin N (5)






Figure S42. HR-ESI-MS of citreoviridin O (6)



**Figure S43.**  ${}^1\text{H}$  NMR spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin O (6)



**Figure S44.**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin O (**6**)




Figure S45. NOESY spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin O (6)

**Single Mass Analysis**

Tolerance = 10.0 mDa / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

1 formula(e) evaluated with 0 results within limits (up to 50 closest results for each mass)


Elements Used:

C: 55-64 H: 0-200 N: 0-15 O: 0-20 Na: 0-1

ZBB-2-Dec 103 (0.408) Cm (97:104)

1: TOF MS ES+


8.99e+006




Minimum: -1.5  
 Maximum: 10.0 10.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
0.0000	---							

**Figure S46.** HR-ESI-MS of pyrenocine A (7)



**Figure S47.**  ${}^1\text{H}$  NMR spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of pyrenocine A (7)



**Figure S48.**  $^{13}\text{C}$  NMR spectrum (100 MHz,  $\text{CD}_3\text{OD}$ ) of pyrenocine A (7)

**Single Mass Analysis**

Tolerance = 10.0 mDa / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions


1 formula(e) evaluated with 0 results within limits (up to 50 closest results for each mass)


Elements Used:

C: 10-50 H: 0-200 N: 0-15 O: 0-20 Na: 0-1


ZBB-13-Dec 110 (0.433) Cm (105:112)

1: TOF MS ES+

**Figure S49.** HR-ESI-MS of terrein (14)



**Figure S50.**  ${}^1\text{H}$  NMR spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of terrein (**14**)



**Figure S51.**  $^{13}\text{C}$  NMR spectrum (100 MHz,  $\text{CD}_3\text{OD}$ ) of terrein (**14**)

**Single Mass Analysis**

Tolerance = 10.0 mDa / DBE: min = -10.0, max = 100.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions


1 formula(e) evaluated with 0 results within limits (all results (up to 1000) for each mass)

Elements Used:

ZBB-23-Jan 101 (0.400) Cm (101:102)

1: TOF MS ES+

3.74e+005



Minimum: -10.0

Maximum: 10.0 10.0 100.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
0.0000	---							

**Figure S52.** HR-ESI-MS of citreoviridin (**20**)





Figure S53.  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin (**20**)



**Figure S54.**  $^{13}\text{C}$  NMR spectrum (100 MHz,  $\text{CD}_3\text{OD}$ ) of citreoviridin (**20**)